Trivium Point Advisory LLC Trims Stake in DexCom, Inc. $DXCM

Trivium Point Advisory LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,276 shares of the medical device company’s stock after selling 179 shares during the quarter. Trivium Point Advisory LLC’s holdings in DexCom were worth $286,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Golden State Wealth Management LLC increased its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom in the first quarter valued at approximately $27,000. Anderson Financial Strategies LLC purchased a new stake in shares of DexCom in the first quarter valued at approximately $37,000. Alpine Bank Wealth Management purchased a new stake in shares of DexCom in the first quarter valued at approximately $40,000. Finally, Private Trust Co. NA increased its position in shares of DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after buying an additional 335 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

DXCM opened at $66.08 on Thursday. The stock’s 50-day moving average price is $77.16 and its 200 day moving average price is $77.94. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a market cap of $25.91 billion, a price-to-earnings ratio of 45.89, a PEG ratio of 1.41 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the company earned $0.43 EPS. DexCom’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 in the last quarter. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on DXCM. Mizuho boosted their price objective on DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Canaccord Genuity Group reiterated a “buy” rating and set a $106.00 price target on shares of DexCom in a research report on Monday. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. UBS Group boosted their price target on DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Finally, The Goldman Sachs Group lowered their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.32.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.